Omeros to terminate Yartemlea compassionate-use program in Europe due to US demand
OMER•Omeros will terminate its Yartemlea compassionate-use program in Europe due to U.S. demand after receiving a negative CHMP opinion on its narsoplimab marketing application. The company plans clinical studies in ARDS and high-risk pediatric TA-TMA later this year.
1. European program ends
Omeros said it will terminate its Yartemlea compassionate-use program in Europe due to U.S. demand. The company received a negative opinion from the CHMP following re-examination of its European marketing authorization application for narsoplimab in TA-TMA.
2. Planned clinical studies
Omeros plans clinical studies in ARDS and high-risk TA-TMA in pediatric patients later this year.
